

REMARKS

Claims 1-58 were pending. Upon entry of this amendment, Claims 38-39, 42-46, 56 and 59-71 will be pending. Support for new Claims 59-71 is found in the specification.

In accordance with the restriction requirement, and to expedite prosecution of this application, only claims pertaining to use of the compound having formula III, and pharmaceutically acceptable salts thereof, for inhibiting bone metastases, preventing new bone metastases and inhibiting metastatic growth in patients having prostate cancer, are presented.

The amendment accompanying these remarks cancels Claims 1-37, 40-41, 47-55 and 57-58, without prejudice to their presentation in a continuation or divisional application. Cancelled claims pertain to either a non-elected invention or an invention not pertaining to use of the compound of formula III in patients having prostate cancer. The remaining claims have been amended, as necessary, to more specifically define the invention, retain continuity, correct minor typographical errors and grammatical inconsistencies, eliminate redundancies, and recite proper Markush terminology.

CONCLUSION

Cancelled subject matter is presented in co-pending divisional applications. Allowance of Claims 38-39, 42-46, 56, and 59-71 is respectfully requested.

Respectfully submitted,  
T. Janus, et al.

23492

ABBOTT LABORATORIES  
Telephone: (847) 937-3810  
Facsimile: (847) 938-2623

  
B. Gregory Donner  
Registration No. 34,580  
Agent for Applicants